|
福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.64 (2018) >
このアイテムの引用には次の識別子を使用してください:
http://ir.fmu.ac.jp/dspace/handle/123456789/693
|
| タイトル: | Immunotherapy for esophageal squamous cell carcinoma: a review |
| 著者: | Mimura, Kosaku
Yamada, Leo
Ujiie, Daisuke
Hayase, Suguru
Tada, Takeshi
Hanayama, Hiroyuki
Aung Kyi Thar Min
Shibata, Masahiko
Momma, Tomoyuki
Saze, Zenichiro
Ohki, Shinji
Kono, Koji |
| 学内所属: | 消化管外科学講座
先端がん免疫治療学講座
プログレッシブDOHaD研究講座 |
| 誌名/書名: | Fukushima Journal of Medical Science |
| 巻: | 64 |
| 号: | 2 |
| 開始ページ: | 46 |
| 終了ページ: | 53 |
| 発行日: | 2018年 |
| 抄録: | Cancer vaccines and immune checkpoint inhibitors (ICI) have recently been employed as immunotherapies for esophageal squamous cell carcinoma (ESCC). Cancer vaccines for ESCC have yielded several promising results from investigator-initiated phase I and II clinical trials. Furthermore, a Randomized Controlled Trial as an adjuvant setting after curative surgery is in progress in Japan. On the other hand, ICI, anti-CTLA-4 mAb and anti-PD-1 mAb, have demonstrated tumor shrinkage and improved overall survival in patients with multiple cancer types. For ESCC, several clinical trials using anti-PD-1/anti-PD-L1 mAb are underway with several recent promising results. In this review, cancer vaccines and ICI are discussed as novel therapeutic strategies for ESCC. |
| 出版者: | The Fukushima Society of Medical Science |
| 出版者（異表記）: | 福島医学会 |
| 本文の言語: | eng |
| このページのURI: | http://ir.fmu.ac.jp/dspace/handle/123456789/693 |
| 本文URL: | https://ir.fmu.ac.jp/dspace/bitstream/123456789/693/1/FksmJMedSci_64_p46.pdf |
| ISSN: | 0016-2590
2185-4610 |
| DOI: | 10.5387/fms.2018-09 |
| PubMed番号: | 30058598 |
| 関連ページ: | https://doi.org/10.5387/fms.2018-09 |
| 権利情報: | © 2018 The Fukushima Society of Medical Science |
| 出現コレクション: | Vol.64 (2018)
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|
